Asthma, Allergic Rhinitis
Conditions
Keywords
Asthma, Allergic rhinitis, Respiratory disease, Allergy, Lipoic acid, Thioctic acid, Antioxidant, Oxidative stress
Brief summary
The aim of the study is to use the antioxidant and antiinflammatory effects of lipoic acid to improve the quality of life of patients with asthma. The investigators will administrate 600 mg lipoic acid orally on a daily basis during two months concurrent with the patient anti-asthmatic therapy and evaluate the effects on resulting pulmonary function, inflammatory and oxidative stress biomarkers and health-related quality of life previous to the initial of the treatment and at 60 days of the supplementary therapy.
Detailed description
Asthma is an inflammatory disease of high prevalence around the world. During development of asthma the presence of oxidative stress has been related to susceptibility and severity of the disease, thus making the use of antioxidant adjuvant therapy with lipoic acid (LA) an interesting treatment option. The objective of the study is to evaluate the efficacy of LA as an adjuvant treatment on functional, antioxidant, inflammatory, quality and control parameters of asthma in human subjects. The trial design is a randomized, double blind, placebo controlled parallel study. Adult patients (\>18 years) with history of mild intermittent to moderate asthma according to the Global Initiative for Asthma (GINA) guidelines were enrolled. It was required a positive skin prick test (\>3 mm) for at least two regional allergens. Patients were randomly assigned to receive lipoic acid or placebo for 60 days. Participants had an intermediate visit to the attending physician one month after initial of treatment to monitor adverse events and to undergo laboratory tests. 1. Introduction. Asthma is an inflammatory disease of high prevalence around the world. During development of asthma the presence of oxidative stress has been related to susceptibility and severity of the disease, thus making the use of antioxidant adjuvant therapy with lipoic acid (LA) an interesting treatment option. 2. Study design. A randomized, double blind, placebo controlled parallel study 3. Methods. Participants and interventions: 55 patients with mild to moderate asthma from Hospital Civil Juan I. Menchaca in Guadalajara, Jalisco, México were included and randomized in block of 10 to receive; LA (600 mg/day) or placebo for eight weeks from January to October of 2011. 4. Objective. To evaluate the efficacy of LA as an adjuvant treatment on functional, antioxidant, inflammatory, quality and control parameters of asthma in human subjects. Primary outcome: change on Forced expiratory volume in 1 second (FEV1), secondary outcomes were levels of Oxygen radical absorbance capacity (ORAC), glutathione (GSH), glutathione disulfide (GSSG), protein carbonyls, differential count of sputum cells, interleukin-4 (IL-4) and scores of quality of life and control of asthma questionnaires.
Interventions
DIETARY_SUPPLEMENTLipoic acid
Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
DIETARY_SUPPLEMENTPlacebo
Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
Sponsors
National Council of Science and Technology, Mexico
University of Guadalajara
Hospital Civil Juan I. Menchaca
Centro Universitario de Ciencias de la Salud, Mexico
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Outpatients (≥18 and ≤ 75 years of age) female or male * Willingness to participate and comply with procedures by signing a written informed consent * Moderate/severe persistent allergic rhinitis according to Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines with a history of intermittent, mild persistent or moderate persistent asthma according to GINA guidelines * Confirmed allergy to at least one of the following allergen preparations: house dust mite f; house dust mite p; cockroach; bush mix; tree mix; grass mix; weed mix, cat; or dog. * All prior medication washout times had been observed * Female volunteers of childbearing potential had to agree to use a medically accepted method of contraception * Negative urine pregnancy test * Without a concomitant chronic medical condition (e.g., significant cardiovascular disease, diabetes requiring medication, chronic kidney disease, chronic thyroid disease, or coagulation defects) * Willingness to adhere to the dosing and visit schedules
Exclusion criteria
* Pregnant or breastfeeding * Female who was or intended to become pregnant during the study or within 12 weeks after study completion * Taking medications prohibited during the study or had not complied with the requirements for the designated washout periods for any of the prohibited medications * Anatomical abnormalities of the nose (turbinate hypertrophy, septal deviation, polyps) * Acute or chronic sinusitis currently being treated with antibiotics and/or topical or oral decongestants * Upper respiratory tract or sinus infection that required antibiotic therapy and had not had at least a 14-day wash-out period prior to the run-in period * Patients undergoing a progressive course of immunotherapy. Subjects on a regular maintenance schedule prior to the screening visit are eligible for study inclusion; however, subject could not receive hyposensitization treatment within 24 hours prior to any study visit * Concomitant medical problem * In a situation or condition that could interfere with participation in the study * Allergic or sensitivity to the study drug or its excipients * History of inadequate adherence to treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Spirometric FVC Values at Baseline | Baseline | Measurement of spirometric predicted parameters at baseline. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. |
| Spirometric FVC Values at Endpoint | 60 days | Measurement of spirometric predicted parameters at the baseline and after 60 days of treatment: Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters. |
| Spirometric FEV1 Values at Baseline | Baseline | Measurement of spirometric predicted parameters at baseline: Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. |
| Spirometric FEV1 Values at Endpoint | 60 days | Measurement of spirometric predicted parameters after 60 days of treatment. Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration. |
| Spirometric FEF Values at Baseline | Baseline | Measurement of spirometric parameters at baseline: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. |
| Spirometric FEF Values at Endpoint | 60 days | Measurement of spirometric FEF after 60 days of treatment: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory Interleukin-4 (IL-4) Sputum Levels at Baseline | Baseline | Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of immunoglobulin E (IgE) in B cells. IL-4 was measured by ELISA. |
| Inflammatory IL-4 Sputum Levels at Endpoint | 60 days | Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of IgE in B cells. IL-4 was measured by ELISA. |
| Measurement of Quality of Life With the ACT (Asthma Control Test) at Baseline | Baseline | Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). |
| Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Baseline | Baseline | Induced sputum of GSH and GSSG levels at baseline. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. |
| Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Baseline | Baseline | The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html). |
| Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Endpoint | 60 days | The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html). |
| Measurement of Quality of Life With the ACT (Asthma Control Test) at Endpoint | 60 days | Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma). |
| Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Endpoint | 60 days | Change in the induced sputum of antioxidant parameters GSH and GSSG levels after 60 days of treatment. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay. |
| Induced Sputum Carbonylated Proteins at Baseline | Baseline | Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products |
| Induced Sputum Carbonylated Proteins at Endpoint | 60 days | Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products. |
| Induced Sputum Eosinophils at Baseline | Baseline | Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. |
| Induced Sputum Eosinophils at Endpoint | 60 days | Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma. |
Countries
Mexico
Participant flow
Recruitment details
82 adult patients (\>18 years) with history of mild intermittent to moderate asthma according to the Global Initiative for Asthma (GINA) guidelines were screened to participate in the study. Recruitment period: January-September 2011.
Pre-assignment details
55 patients were enrolled in the study prior to randomization and group assignment. From the 82 patients initially screened, 12 patients declined to participate and 15 patients did not meet the inclusion criteria.
Participants by arm
| Arm | Count |
|---|---|
| Lipoic Acid Lipoic acid (ALA) 600 mg oral dose (two 300 mg capsules) once daily in the morning during 60 days | 28 |
| Placebo Placebo (two 300 mg capsules filled with vehicle) orally once daily in the morning during 60 days | 27 |
| Total | 55 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Discontinued intervention (GERD) | 1 | 0 |
| Overall Study | Exclusion criteria, asthma exacerbation | 0 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 2 |
Baseline characteristics
| Characteristic | Lipoic Acid | Placebo | Total |
|---|---|---|---|
| Age Continuous | 40.9 years STANDARD_DEVIATION 10.5 | 43.8 years STANDARD_DEVIATION 16.6 | 42.3 years STANDARD_DEVIATION 13.6 |
| Body mass index (BMI) | 29.9 Kg/m^2 STANDARD_DEVIATION 5.4 | 28.0 Kg/m^2 STANDARD_DEVIATION 5 | 29.0 Kg/m^2 STANDARD_DEVIATION 5.2 |
| Region of Enrollment Mexico | 28 participants | 27 participants | 55 participants |
| Sex: Female, Male Female | 16 Participants | 15 Participants | 31 Participants |
| Sex: Female, Male Male | 12 Participants | 12 Participants | 24 Participants |
| Weight | 73.6 Kg STANDARD_DEVIATION 16.1 | 74.1 Kg STANDARD_DEVIATION 15.9 | 73.8 Kg STANDARD_DEVIATION 16 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 23 | 0 / 24 |
| serious Total, serious adverse events | 0 / 23 | 0 / 24 |
Outcome results
Primary
Spirometric FEF Values at Baseline
Measurement of spirometric parameters at baseline: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Spirometric FEF Values at Baseline | 4.89 Liters/sec | Standard Deviation 1.72 |
| Placebo | Spirometric FEF Values at Baseline | 6.09 Liters/sec | Standard Deviation 1.96 |
Primary
Spirometric FEF Values at Endpoint
Measurement of spirometric FEF after 60 days of treatment: Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration.
Time frame: 60 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Spirometric FEF Values at Endpoint | 5.47 Liters/sec | Standard Deviation 1.53 |
| Placebo | Spirometric FEF Values at Endpoint | 6.10 Liters/sec | Standard Deviation 1.68 |
Primary
Spirometric FEV1 Values at Baseline
Measurement of spirometric predicted parameters at baseline: Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Spirometric FEV1 Values at Baseline | 2.01 Liters | Standard Deviation 0.63 |
| Placebo | Spirometric FEV1 Values at Baseline | 2.37 Liters | Standard Deviation 0.65 |
Primary
Spirometric FEV1 Values at Endpoint
Measurement of spirometric predicted parameters after 60 days of treatment. Forced expiratory volume in 1 second (FEV1), volume that has been exhaled at the end of the first second of forced expiration.
Time frame: 60 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Spirometric FEV1 Values at Endpoint | 2.26 Liters | Standard Deviation 0.69 |
| Placebo | Spirometric FEV1 Values at Endpoint | 2.35 Liters | Standard Deviation 0.66 |
Primary
Spirometric FVC Values at Baseline
Measurement of spirometric predicted parameters at baseline. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Spirometric FVC Values at Baseline | 2.74 Liters | Standard Deviation 0.68 |
| Placebo | Spirometric FVC Values at Baseline | 3.07 Liters | Standard Deviation 0.76 |
Primary
Spirometric FVC Values at Endpoint
Measurement of spirometric predicted parameters at the baseline and after 60 days of treatment: Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, measured in liters.
Time frame: 60 days
Population: Per protocol
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Spirometric FVC Values at Endpoint | 2.82 Liters | Standard Deviation 0.77 |
| Placebo | Spirometric FVC Values at Endpoint | 3.06 Liters | Standard Deviation 0.71 |
Secondary
Induced Sputum Carbonylated Proteins at Baseline
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Induced Sputum Carbonylated Proteins at Baseline | 7.5 nmol/mg | Standard Deviation 4.37 |
| Placebo | Induced Sputum Carbonylated Proteins at Baseline | 10.12 nmol/mg | Standard Deviation 10.81 |
Secondary
Induced Sputum Carbonylated Proteins at Endpoint
Proteins can become modified by a large number of reactions involving reactive oxygen species. Among these, carbonylation is an irreversible and unrepairable oxidative reaction. The main protein modifications originated from oxidative stress comprise direct oxidation of aminoacids with a thiol group, such as cysteine, oxidative glycation, and carbonylation. Oxidative protein carbonylation induce protein degradation in a nonspecific manner. Chemically, oxidative carbonylation preferentially occurs at proline, threonine, lysine, and arginine, presumably through a metal-catalyzed activation of hydrogen peroxide to a reactive intermediate. Carbonylation usually refers to a process that forms reactive ketones or aldehydes that can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct oxidation of side chains of lysine, arginine, proline, and threonine residues, among other aminoacids, produces DNPH detectable protein products.
Time frame: 60 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Induced Sputum Carbonylated Proteins at Endpoint | 3.24 nmol/mg | Standard Deviation 2.2 |
| Placebo | Induced Sputum Carbonylated Proteins at Endpoint | 4.21 nmol/mg | Standard Deviation 2.47 |
Secondary
Induced Sputum Eosinophils at Baseline
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma.
Time frame: Baseline
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Lipoic Acid | Induced Sputum Eosinophils at Baseline | 12.88 Eosinophil percentage in sputum cells |
| Placebo | Induced Sputum Eosinophils at Baseline | 6.10 Eosinophil percentage in sputum cells |
Secondary
Induced Sputum Eosinophils at Endpoint
Eosinophils, a prominent feature of asthma, are found in increased numbers in the circulation and sputum, usually in relation to the severity of asthma.
Time frame: 60 days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Lipoic Acid | Induced Sputum Eosinophils at Endpoint | 6.39 Eosinophil percentage in sputum cells |
| Placebo | Induced Sputum Eosinophils at Endpoint | 5.68 Eosinophil percentage in sputum cells |
Secondary
Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Baseline
Induced sputum of GSH and GSSG levels at baseline. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay.
Time frame: Baseline
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Lipoic Acid | Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Baseline | 81.42 ratio |
| Placebo | Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Baseline | 35.77 ratio |
Secondary
Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Endpoint
Change in the induced sputum of antioxidant parameters GSH and GSSG levels after 60 days of treatment. The ratio GSH/GSSG is considered an index of antioxidant status and reductive -SH groups. GSH and GSSG were measured by a microplate fluorescent assay.
Time frame: 60 days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Lipoic Acid | Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Endpoint | 58.6 ratio |
| Placebo | Induced Sputum of Glutathione (GSH)/Glutathione Disulfide (GSSG) Ratio at Endpoint | 37.5 ratio |
Secondary
Inflammatory IL-4 Sputum Levels at Endpoint
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of IgE in B cells. IL-4 was measured by ELISA.
Time frame: 60 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Inflammatory IL-4 Sputum Levels at Endpoint | 14.53 pg/mL | Standard Deviation 12.96 |
| Placebo | Inflammatory IL-4 Sputum Levels at Endpoint | 23.19 pg/mL | Standard Deviation 34.39 |
Secondary
Inflammatory Interleukin-4 (IL-4) Sputum Levels at Baseline
Inflammatory IL-4 sputum levels after 60 days of treatment. Sputum induction is a semi-invasive technique used to detect and monitor airway inflammation. IL-4 is a Th2 cytokine that promote airway inflammation in asthma. IL-4 drives the production of immunoglobulin E (IgE) in B cells. IL-4 was measured by ELISA.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Inflammatory Interleukin-4 (IL-4) Sputum Levels at Baseline | 37.77 pg/mL | Standard Deviation 38.04 |
| Placebo | Inflammatory Interleukin-4 (IL-4) Sputum Levels at Baseline | 39.90 pg/mL | Standard Deviation 50.03 |
Secondary
Measurement of Quality of Life With the ACT (Asthma Control Test) at Baseline
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma).
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Measurement of Quality of Life With the ACT (Asthma Control Test) at Baseline | 13.65 units on a scale | Standard Deviation 4.35 |
| Placebo | Measurement of Quality of Life With the ACT (Asthma Control Test) at Baseline | 14.46 units on a scale | Standard Deviation 4.85 |
Secondary
Measurement of Quality of Life With the ACT (Asthma Control Test) at Endpoint
Assessment of Quality of life scores with the ACT (Asthma Control Test). The ACT is a way to determine if the asthma symptoms are well controlled. The Asthma Control Test™ (ACT™) is a five question health survey used to measure asthma control in individuals 12 years of age and older. The survey measures the elements of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI). ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. Each item includes 5 response options corresponding to a 5-point Likert-type rating scale. In scoring the ACT survey, responses for each of the 5 items are summed to yield a score ranging from 5 (poor control of asthma) to 25 (complete control of asthma).
Time frame: 60 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Measurement of Quality of Life With the ACT (Asthma Control Test) at Endpoint | 19.13 units on a scale | Standard Deviation 3.62 |
| Placebo | Measurement of Quality of Life With the ACT (Asthma Control Test) at Endpoint | 17.71 units on a scale | Standard Deviation 4.03 |
Secondary
Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Baseline
The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html).
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Baseline | 3.86 units on a scale | Standard Deviation 1.32 |
| Placebo | Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Baseline | 3.72 units on a scale | Standard Deviation 1.61 |
Secondary
Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Endpoint
The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains (http://www.qoltech.co.uk/aqlq.html).
Time frame: 60 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lipoic Acid | Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Endpoint | 5.57 units on a scale | Standard Deviation 1.17 |
| Placebo | Measurement of Quality of Life With the AQLQ (Asthma Quality of Life Questionnaire) at Endpoint | 5.10 units on a scale | Standard Deviation 1.24 |